Baylor Genetics announced it was awarded a multi-year national contract from the United States Department of Veterans Affairs (VA) to deliver pharmacogenomic (PGx) testing and germline genetic testing services, which includes hereditary cancer testing to veterans across the VA healthcare system.
“Baylor Genetics is deeply honored to support the VA in expanding nationwide access to advanced precision diagnostics for veterans,” said Kengo Takishima, Chairman and CEO of Baylor Genetics. “We aim to empower VA providers with the tools they need to improve treatment outcomes and ensure that those who have served our country receive the best possible care.”
PGx testing works by analyzing a person’s genes to understand how they may respond to certain medications, such as antidepressants. When identifying variations in genes that influence drug metabolism and effectiveness, PGx testing can empower healthcare providers to tailor treatments, which can help reduce side effects, shorten the time to relief, and improve overall outcomes for patients that deal with mental health conditions.
Hereditary cancer testing can help identify risk and inform active surveillance. These insights can help support treatment decisions, guide surveillance for additional cancers, and potentially identify at-risk family members.
Both PGx and germline cancer testing are available to all veterans.
Baylor Genetics has the announcement
